
|Articles|January 11, 2017
Generic Pharmaceutical Association (GPhA) Statement Regarding President-Elect Trump's Remarks on the Pharmaceutical Industry
Advertisement
PRESS RELEASE
"We understand the President-Elect's concerns about drug prices. Patients and drug purchasers like the federal government, health systems, employers and others, rely on access to more affordable medicines. Study after study demonstrates that generic medicines drive down drug costs through competition. Still, more can be done to increase competition and we look forward to working with the new Administration to reduce the backlog of generic drug applications at FDA, and on initiatives that bring more generic and biosimilar products to the market. Our recommendations to the Trump administration can be found
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
3
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5


































































































































